Enfusion, Inc. (NYSE:ENFN - Get Free Report) Director Deirdre Somers sold 1,637 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.53, for a total transaction of $17,237.61. Following the completion of the sale, the director now owns 41,675 shares of the company's stock, valued at approximately $438,837.75. This represents a 3.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
NYSE ENFN traded up $0.10 during trading on Wednesday, reaching $10.91. The company's stock had a trading volume of 1,645,948 shares, compared to its average volume of 1,406,472. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of 272.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a 12 month low of $7.52 and a 12 month high of $11.38. The firm has a 50 day moving average price of $10.19 and a 200 day moving average price of $9.23.
A number of equities analysts have weighed in on ENFN shares. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. William Blair reiterated a "market perform" rating on shares of Enfusion in a research note on Monday. Finally, Stifel Nicolaus raised their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Enfusion has an average rating of "Hold" and a consensus price target of $10.25.
Read Our Latest Stock Report on Enfusion
A number of institutional investors have recently modified their holdings of ENFN. TenCore Partners LP acquired a new position in Enfusion in the third quarter valued at about $3,938,000. Dimensional Fund Advisors LP boosted its position in shares of Enfusion by 57.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company's stock worth $4,466,000 after acquiring an additional 191,436 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock valued at $1,974,000 after acquiring an additional 178,821 shares during the last quarter. Impax Asset Management Group plc raised its position in Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock valued at $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Finally, Scalar Gauge Management LLC lifted its stake in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company's stock worth $5,227,000 after purchasing an additional 110,000 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Enfusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.
While Enfusion currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.